Spinal cord stimulator lawsuits are accelerating in 2026, with injured patients pursuing claims against some of the world’s largest medical device manufacturers. On June 5, 2026, the U.S. Judicial Panel on Multidistrict Litigation formally established MDL 3181, centralizing federal spinal cord stimulator lawsuit claims against Boston Scientific and Abbott Laboratories in the Central District of California. Meanwhile, plaintiffs have asked the JPML to create a separate MDL for Nevro spinal cord stimulator lawsuits, and litigation against Medtronic continues on its own track. If you or someone you love suffered injuries from a spinal cord stimulator device — lead migration, electrical burns, nerve damage, or worse — these developments directly affect your legal options right now.
What Is MDL 3181 and Why Does It Matter?
The JPML’s June 5, 2026 order created a proceeding officially titled IN RE: Abbott Laboratories and Boston Scientific Corporation Spinal Cord Stimulator Products Liability Litigation. The case has been assigned to Judge Josephine L. Staton in the Central District of California, one of the nation’s busiest federal courts for complex civil litigation. As of July 1, 2026, there are 24 pending actions in the Boston Scientific spinal cord stimulator MDL, drawn from federal districts across the country.
The MDL formation came after plaintiffs filed a consolidation motion on February 20, 2026, arguing that the cases shared overlapping factual questions about regulatory compliance, device performance, and failure to warn. At the time that motion was filed, at least 15 federal lawsuits were already pending, and an estimated 400 additional injured patients had already retained legal counsel. That number is almost certainly higher today. Critically, the JPML declined to create a broader industry-wide MDL that would have swept in Medtronic and Nevro devices — those claims are proceeding on separate tracks. As of mid-2026, plaintiffs have separately asked the JPML to centralize Nevro spinal cord stimulator lawsuits in a new MDL, keeping MDL 3181 focused squarely on Boston Scientific and Abbott products.
The Injuries Driving the Spinal Cord Stimulator Lawsuit Wave
Spinal cord stimulators are implanted devices designed to manage chronic pain by delivering mild electrical impulses to the spinal cord. When they work as intended, they can meaningfully reduce reliance on opioids and improve quality of life. When they fail, the consequences can be catastrophic and permanent. The injuries alleged across the spinal cord stimulator lawsuit filings consolidated into MDL 3181 include:
- Lead migration — the electrode leads shift from their implanted position, delivering stimulation to unintended areas of the spinal cord
- Lead fracture — leads break inside the body, requiring surgical revision
- Painful electrical shocks — patients report sudden, uncontrolled jolts of electricity
- Thermal burns — overheating components cause internal tissue damage
- Autonomic dysfunction — disruption of involuntary body systems including heart rate, blood pressure, and bladder function
- Nerve damage and neurological injury — permanent loss of sensation or motor function
- Worsening of original pain condition
- Paralysis — in the most severe reported cases
- Device infection requiring explant surgery
Revision surgery to reposition, repair, or remove a malfunctioning spinal cord stimulator is itself a high-risk procedure. Many plaintiffs allege that a device meant to reduce suffering instead left them permanently worse off than before implantation. If you have experienced any of these complications, speaking with a qualified mass tort attorney about your legal options is an important first step.
The FDA’s Alarming Adverse Event Record
The scale of reported harm associated with spinal cord stimulators is difficult to overstate. According to data compiled by Drugwatch in August 2026, more than 80,000 adverse event reports involving spinal cord stimulators have been filed with the FDA since 2008, including nearly 500 reported deaths. These figures are drawn from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, which captures voluntary and mandatory reports submitted by manufacturers, healthcare facilities, and patients.
Experts note that adverse event databases like MAUDE are widely believed to capture only a fraction of actual device-related complications, as reporting by patients and physicians remains inconsistent and often voluntary. The true number of patients harmed by spinal cord stimulator malfunctions may be substantially higher than what the FDA’s records reflect. Plaintiffs’ attorneys in MDL 3181 and related proceedings are expected to use the MAUDE data aggressively to argue that manufacturers had long-standing knowledge of device failure patterns and failed to adequately warn patients and physicians.
Abbott’s Class 1 Recall and the PMA Supplement Allegations
One of the most significant factual allegations in the spinal cord stimulator litigation involves Abbott Laboratories and its 2023 Class 1 recall — the FDA’s most serious recall classification, reserved for situations where use of a product may cause serious injury or death. The recalled devices were found to have the potential to deliver unintended electrical stimulation, which could cause painful shocks, burns, or neurological injury.
Beyond the recall itself, plaintiffs allege that Abbott made design and manufacturing changes to its spinal cord stimulator products through the FDA’s Premarket Approval (PMA) supplement process without obtaining the level of regulatory scrutiny those changes warranted. The core allegation is that Abbott sought to introduce modifications that materially affected device safety and performance by characterizing them as minor supplements — a regulatory shortcut that, plaintiffs argue, allowed dangerous design changes to reach implanted patients without adequate independent review. These allegations, if proven at trial, could support findings of fraud on the FDA and potentially strip Abbott of federal preemption defenses that device manufacturers frequently rely upon to defeat state-law failure-to-warn claims.
MDL 3181 vs. a Class Action: What Injured Patients Need to Know
When news reports describe thousands of plaintiffs suing the same defendant over the same product, many people assume the proceeding is a class action lawsuit. MDL 3181 is not a class action, and that distinction matters enormously to injured patients evaluating their options.
In a class action, a small number of named plaintiffs represent an entire class of similarly situated individuals. Any settlement or judgment applies uniformly across the class, and individual class members typically have limited input into the litigation strategy. Compensation amounts are often modest because they are divided among potentially millions of claimants.
An MDL works differently. Each plaintiff in MDL 3181 retains their own individual lawsuit with their own attorney. The MDL mechanism simply consolidates pretrial proceedings — discovery, motion practice, and bellwether trials — before a single federal judge to eliminate duplicative litigation and create consistent rulings on shared legal questions. When cases resolve, they resolve individually, based on each plaintiff’s specific injuries, medical history, and damages. This structure means that a plaintiff with severe permanent neurological injuries may receive substantially more compensation than a plaintiff who required a single revision surgery, even though both cases are part of the same MDL.
As of August 2026, lawsuits against Abbott, Medtronic, Boston Scientific, and Nevro are progressing through various stages of litigation, but no settlements or jury verdicts have been reached in any of the major spinal cord stimulator proceedings. The litigation remains in relatively early stages, and injured patients who have not yet filed a claim should be aware that statutes of limitations — which vary by state — continue to run.
Who Qualifies for the Spinal Cord Stimulator Lawsuit?
Eligibility for the spinal cord stimulator MDL or related individual litigation generally depends on several factors that attorneys evaluate during an initial case review. While every case is different, the following criteria are broadly relevant to determining whether a potential claim has merit:
- You received an implanted spinal cord stimulator manufactured by Abbott, Boston Scientific, Medtronic, or Nevro
- You experienced a documented device complication — including but not limited to lead migration, lead fracture, electrical shock, thermal injury, infection, autonomic dysfunction, or neurological damage
- Your complication required medical intervention, such as revision surgery, explantation, hospitalization, or emergency treatment
- You suffered measurable harm — physical injury, additional medical expenses, lost income, or diminished quality of life attributable to the device failure
- Your injuries occurred within the applicable statute of limitations for your state — typically two to three years from the date you knew or should have known your injury was related to the device
Patients who received devices subject to Abbott’s 2023 Class 1 recall may have particularly strong claims, especially if they were not timely notified of the recall or were advised to continue using the device despite the known risk. Patients whose treating physicians received recall notices but did not communicate the risk to them may have additional claims against healthcare providers.
Estimated settlement values in spinal cord stimulator cases vary significantly based on the nature and severity of the harm. According to the Lawsuit Information Center, as of August 2026, settlement amounts range from lower six figures for documented revision surgery cases to more than $1 million for cases involving permanent neurological or autonomic injury. These are estimates based on the types of damages typically sought in complex medical device litigation — no settlements have been publicly announced in the current proceedings, and actual outcomes will depend on individual case facts and the overall trajectory of MDL 3181 and related litigation.
Frequently Asked Questions About the Spinal Cord Stimulator Lawsuit MDL
What is MDL 3181 and when was it created?
MDL 3181 is a federal multidistrict litigation proceeding officially titled IN RE: Abbott Laboratories and Boston Scientific Corporation Spinal Cord Stimulator Products Liability Litigation. It was created by order of the U.S. Judicial Panel on Multidistrict Litigation on June 5, 2026, and is assigned to Judge Josephine L. Staton in the Central District of California. As of July 2026, there are 24 pending actions in the MDL. The proceeding consolidates pretrial proceedings for individual federal lawsuits alleging injuries caused by Abbott and Boston Scientific spinal cord stimulator devices.
What injuries are covered in the spinal cord stimulator lawsuits?
The lawsuits encompass a wide range of injuries associated with spinal cord stimulator failure, including lead migration, lead fracture, unintended electrical shocks, thermal burns, infection, autonomic dysfunction, nerve damage, worsening of the underlying pain condition, and in the most serious cases, paralysis. Injuries requiring revision surgery or explantation are among the most common bases for claims. Since 2008, more than 80,000 adverse event reports related to spinal cord stimulators have been filed with the FDA, including nearly 500 reported deaths, underscoring the scale of harm associated with these devices.
What was Abbott’s 2023 Class 1 Recall about?
Abbott issued a Class 1 recall — the FDA’s most serious category — in 2023 for certain spinal cord stimulator devices found to have the potential to deliver unintended electrical stimulation. The recall is central to MDL 3181 litigation, with plaintiffs alleging that Abbott knew or should have known about device performance issues and failed to adequately warn patients and physicians. Plaintiffs also allege that Abbott made design or manufacturing changes through the PMA supplement process in ways that circumvented the full regulatory review those changes required.
How is an MDL different from a class action lawsuit?
Unlike a class action, an MDL does not merge individual plaintiffs into a single collective claim. Each plaintiff in MDL 3181 retains their own lawsuit and their own attorney. The MDL structure coordinates pretrial discovery and motion practice before one judge to promote efficiency and consistent rulings, but individual cases are resolved separately based on each plaintiff’s specific injuries and damages. This means compensation is tailored to individual harm rather than divided uniformly among all claimants.
How much compensation could a spinal cord stimulator lawsuit be worth?
Estimated settlement values vary considerably depending on the severity of a plaintiff’s injuries. As of August 2026, analysts estimate that settlement amounts could range from lower six figures for cases involving a documented revision surgery to more than $1 million for cases involving permanent neurological or autonomic injury. No settlements or jury verdicts have been reached in the current spinal cord stimulator litigation against Abbott, Boston Scientific, Medtronic, or Nevro as of August 2026. These figures represent estimates based on comparable medical device litigation and should not be taken as guarantees of any particular outcome. An experienced mass tort attorney can provide a more individualized assessment based on the specific facts of your case.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.